Dogwood Therapeutics, Inc.
DWTX
$4.90
$0.102.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 105.37% | 522.31% | 96.20% | -20.20% | -8.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 237.11% | 562.70% | 80.59% | -27.58% | -15.62% |
| Operating Income | -237.11% | -562.70% | -80.59% | 27.58% | 15.62% |
| Income Before Tax | -731.29% | -600.54% | -84.66% | 27.14% | 14.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -746.05% | -600.50% | -84.66% | 27.14% | 14.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -746.05% | -600.50% | -84.66% | 27.14% | 14.87% |
| EBIT | -237.11% | -562.70% | -80.59% | 27.58% | 15.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -404.08% | -339.17% | -27.02% | 41.42% | 18.97% |
| Normalized Basic EPS | -90.37% | -311.79% | -27.02% | 41.42% | 18.97% |
| EPS Diluted | -404.08% | -339.17% | -27.02% | 41.42% | 18.97% |
| Normalized Diluted EPS | -90.37% | -311.79% | -27.02% | 41.42% | 18.97% |
| Average Basic Shares Outstanding | 87.13% | 70.13% | 45.37% | 24.37% | 5.06% |
| Average Diluted Shares Outstanding | 87.13% | 70.13% | 45.37% | 24.37% | 5.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |